OncoSec, 24 North Main Street, Pennington 08534. Daniel O’Connor, CEO. www.oncosec.com.
OncoSec Medical Incorporated, a company developing cancer immunotherapies, has appointed Robert W. Ashworth as vice president of regulatory. The veteran executive has contributed to the FDA approval of 12 new drugs. Oncosec moved its headquarters to Pennington from San Diego late last year and has been staffing up as it continues clinical trials of its “Immunopulse” product (U.S. 1, July 11). Ashworth previously worked at Advaxis, where OncoSec CEO Daniel J. O’Connor was CEO until 2017. He is the second Advaxis executive O’Connor has brought over.
“Over the past year, OncoSec has significantly expanded and accelerated its clinical development activities requiring an individual of Bob’s expertise and experience to manage the overall regulatory processes,” said O’Connor. “Robert will be responsible for leading our global regulatory strategy as we advance our PISCES/KEYNOTE-695 study and other clinical programs.”
At Advaxis Ashworth developed and executed the global regulatory strategy for the company’s immunotherapy platform and served as the company’s regulatory representative for clinical development programs. Ashworth previously worked for NPS Pharmaceuticals, Inc., Biovail, Forest Laboratories, and other firms. He has a bachelor’s in chemistry from St. John’s University and a doctorate in organic chemistry from MIT.
